Salem Investment Counselors’s Pliant Therapeutics PLRX Stock Holding History

Salem Investment Counselors’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-60	Closed	-$791	–	1250
2024 Q4	$791	Hold	60	–	–	﹤0.01%	1105
2024 Q3	$673	Hold	60	–	–	﹤0.01%	1111
2024 Q2	$645	Hold	60	–	–	﹤0.01%	1100
2024 Q1	$894	Hold	60	–	–	﹤0.01%	1098
2023 Q4	$1.09K	Buy	+60	New	+$912	﹤0.01%	1026
2022 Q3	–	Sell	-7,735	Closed	-$62K	–	1101
2022 Q2	$62K	Buy	7,735 +980	+15%	+$6.28K	﹤0.01%	466
2022 Q1	$47K	Buy	6,755 +1,540	+30%	+$15.7K	﹤0.01%	518
2021 Q4	$70K	Buy	5,215 +4,420	+556%	+$70.2K	﹤0.01%	513
2021 Q3	$13K	Buy	795 +725	+1,036%	+$15.4K	﹤0.01%	727
2021 Q2	$2K	Hold	70	–	–	﹤0.01%	841
2021 Q1	$3K	Buy	+70	New	+$2.27K	﹤0.01%	788

Other funds holding PLRX

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Salem Investment Counselors's PLRX Position: Q1 2025 in Review

Salem Investment Counselors sold out of Pliant Therapeutics (PLRX) in Q1 2025, closing a stake of 60 shares — an estimated $791 sold.

Salem Investment Counselors first reported a position in PLRX in Q1 2021 and held it in 11 quarters. The position peaked at $70K in Q4 2021. 140 funds tracked by Wall St. Rank hold PLRX as of Q1 2025.

Salem Investment Counselors reported no remaining Pliant Therapeutics position as of Q1 2025 after selling out during the quarter.
Salem Investment Counselors sold 60 Pliant Therapeutics shares in Q1 2025, an estimated $791.
Salem Investment Counselors first reported a position in Pliant Therapeutics in Q1 2021 and held it in 11 quarters.
Salem Investment Counselors's Pliant Therapeutics position peaked at $70K in Q4 2021.
140 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q1 2025.

Based on Salem Investment Counselors's 13F filing for Q1 2025, filed 16 Apr 2025.